サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1786452

DNAメチル化の世界市場

DNA Methylation

出版日
ページ情報
英文 207 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.50円
DNAメチル化の世界市場
出版日: 2025年08月08日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 207 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

DNAメチル化の世界市場は2030年までに41億米ドルに達する

2024年に18億米ドルと推定されるDNAメチル化の世界市場は、2030年には41億米ドルに達し、分析期間2024-2030年のCAGRは14.6%で成長すると予測されます。本レポートで分析したセグメントの1つであるポリメラーゼ連鎖反応技術は、CAGR 17.4%を記録し、分析期間終了時には20億米ドルに達すると予測されます。マイクロアレイ技術分野の成長率は、分析期間でCAGR 11.6％と推定されます。

米国市場は4億7,610万米ドルと推定、中国はCAGR13.6％で成長予測

米国のDNAメチル化市場は、2024年に4億7,610万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに6億3,110万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは13.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ13.9％と12.3％と予測されています。欧州では、ドイツがCAGR 10.4%で成長すると予測されています。

世界のDNAメチル化市場- 主要動向と促進要因のまとめ

DNAメチル化はエピジェネティック診断と治療における新たなフロンティアを切り開くか？

重要なエピジェネティックメカニズムであるDNAメチル化は、特にがん、神経疾患、自己免疫疾患など、様々な疾患を理解し診断するための重要なバイオマーカーとして浮上しています。DNAのシトシン塩基にメチル基を付加することで、このプロセスは根本的な遺伝暗号を変えることなく遺伝子発現を制御することができます。遺伝子サイレンシング、クロマチンリモデリング、ゲノムの安定性においてその役割を果たすことから、研究および臨床応用の両面で貴重なターゲットとなっています。腫瘍学においては、異常なDNAメチル化パターンは腫瘍形成の早期指標として機能し、時には症状が現れる前であっても、最も初期の段階でがんを検出する高感度診断ツールの開発を可能にしています。現在、リキッドバイオプシー・プラットフォームは、非侵襲的がんスクリーニングのために循環腫瘍DNA（ctDNA）メチル化シグネチャーを活用しており、集団全体の早期発見プログラムに大きな可能性を提供しています。さらに、アルツハイマー病やパーキンソン病のような神経変性疾患では、特定のメチル化変化が早期診断や疾患進行追跡のためのバイオマーカーとして研究されています。このような臨床的有用性の拡大が、バイサルファイト・シーケンス、メチル化アレイ、メチル化特異的PCRなどのハイスループット・メチル化解析技術に対する需要を後押ししています。製薬会社もまた、DNAメチル化を治療標的として研究しており、異常なメチル化を逆転させ、正常な遺伝子機能を回復させるエピジェネティック医薬品の開発を目指しています。臨床および研究コミュニティが様々な組織や疾患におけるメチル化パターンの機能的意味を明らかにし続ける中、健康と疾患におけるエピゲノムの役割に対する理解の高まりに支えられ、DNAメチル化市場は大きな成長を遂げています。

検出技術の革新はDNAメチル化の状況をどのように変えているか？

検出技術の急速な進歩は、研究者や臨床医がDNAメチル化を調査する方法を再構築し、分解能と拡張性の両方を向上させています。メチル化特異的PCRやバイサルファイト変換技術などの従来の方法は、現在も広く使用されていますが、全ゲノムバイサルファイトシーケンス（WGBS）、縮小表示バイサルファイトシーケンス（RRBS）、Oxford NanoporeやPacBioのような化学的治療を必要としない直接メチル化検出を可能にする第3世代シーケンス技術などの次世代プラットフォームによって補完されつつあります。これらの新しいツールは、より高い精度、より広いゲノムカバレッジ、旧来の技術では見逃される可能性のあるメチル化パターンの微妙な変化を検出する能力を提供します。イルミナのInfiniumプラットフォームなどの高スループットメチル化アレイは、現在では1回の実験でゲノム全体の何十万ものCpG部位をプロファイリングすることができ、エピゲノムワイド関連研究（EWAS）に不可欠なものとなっています。さらに、シングルセルメチル化シーケンスは、細胞特異的なエピジェネティックランドスケープに関する洞察を提供し、発生生物学や疾患の不均一性における発見を可能にするため、人気を集めています。人工知能と機械学習の統合は、メチル化に基づく疾患マーカーの自動パターン認識と予測モデリングを可能にすることで、これらの能力をさらに増幅させています。さらに、特に低資源環境におけるがん診断のために、携帯可能なポイントオブケア型のメチル化検出システムが開発されており、エピジェネティック検査の民主化への推進が強調されています。このような技術革新は、調査効率を高めるだけでなく、発見されたテーマの臨床応用を加速させ、精密医療戦略における中心的な柱として位置づけられています。

個別化医療の重視の高まりは、メチル化ベースのツールの需要を拡大するか？

現在進行中の個別化医療と精密医療へのシフトは、個別化された診断、予後予測、治療方針の決定のためのツールとして、DNAメチル化解析の需要を大幅に押し上げています。例えば、がん治療では、メチル化プロファイリングは、腫瘍のサブタイプ、攻撃性、治療効果の可能性によって患者を層別化するのに役立ち、腫瘍医がより効果的に治療を調整することを可能にします。特に肺がん、乳がん、大腸がんなどでは、メチル化パターンに基づいてコンパニオン診断薬を開発し、特定の薬剤の使用を誘導しています。出生前検査では、非侵襲的出生前スクリーニング（NIPS）において、胎児のDNAと母体のDNAを区別するためにメチル化ベースのアッセイが使用されており、侵襲的な手順を踏むことなく遺伝子異常を検出する精度が高まっています。メチル化バイオマーカーはまた、環境ストレス因子のエピジェネティックな影響とメンタルヘルスへの影響を理解するために精神医学の分野でも研究されており、予測的・予防的介入への道を開いています。さらに、ライフスタイル、栄養、環境暴露がメチロームに影響を与えることが知られているため、消費者志向のエピジェネティック検査サービスが人気を集めており、個人のメチル化プロファイルに基づいて老化、健康状態、疾病素因に関する洞察を提供しています。メチル化データをトランスクリプトミクスやプロテオミクスなどの他のオミクス層と組み合わせることで、総合的な患者プロファイルが作成され、より多くの情報に基づいた臨床的意思決定が可能になります。バイオ製薬企業は、メチル化解析を創薬パイプラインに統合し、新規ターゲットの同定、疾患モデルの検証、エピジェネティックな薬効モニタリングにリアルタイムで利用するようになってきています。患者の期待が進化し、ヘルスケアがより積極的なデータ主導型モデルへとシフトするにつれ、DNAメチル化ベースのソリューションに対する需要は、臨床と消費者向けヘルス分野の両方で拡大する見込みです。

DNAメチル化市場を前進させる主な成長カタリストは？

DNAメチル化市場の成長は、技術的な成熟度、疾病に特化したアプリケーション、進化する臨床行為、精密診断に対するユーザーの需要に根ざしたいくつかの要因によってもたらされます。なかでも、がん診断、特に早期発見とモニタリングにおけるメチル化バイオマーカーの役割が拡大しており、メチル化シグネチャーは従来の遺伝子変異と比較して優れた感度を提供しています。このため、FDA承認のアッセイを含む新しいリキッドバイオプシー検査の開発と商業化が進み、がんの診断と管理の方法が変わりつつあります。さらに、マルチオミクス研究の台頭は、生物学的知見創出の中核要素としてメチル化解析を含む統合プラットフォームへの需要を煽っています。神経変性、自己免疫疾患、代謝症候群のような複雑な慢性疾患の有病率の増加は、メチル化が重要な焦点として浮上しているエピジェネティックなメカニズムのより包括的な調査を促しています。さらに、検査の分散化や在宅化の動向は、検査室レベルの精度を維持しつつ、簡便で使いやすいメチル化アッセイの必要性を生み出しています。研究機関側では、学術研究イニシアティブや公衆衛生プログラムが、政府や慈善団体からの資金提供の増加に支えられ、集団レベルの疾患リスクを理解するために大規模なメチル化プロファイリングを取り入れています。クラウドベースのバイオインフォマティクス・ツールとスケーラブルな分析が利用可能になったことで、リソースに制約のある環境でもメチル化技術を幅広く採用できるようになっています。一方、製薬企業はメチル化プロファイリングを用いて、標的治療の対象となる患者サブセットを特定し、特にエピジェネティック医薬品の開発において、薬剤の有効性をモニターしています。最後に、規制当局の承認が進み、メチル化に基づく診断のための標準化フレームワークが出現したことで、市場での採用を拡大するために必要な検証と信頼がもたらされています。これらの多様でありながら相互に関連する促進要因が相まって、医療と分子研究の将来において、メチル化診断市場がより顕著でインパクトのある役割を果たすようになっています。

セグメント

技術（ポリメラーゼ連鎖反応技術、マイクロアレイ技術、シーケンス技術、その他技術）、製品（消耗品、キット・試薬、酵素、機器・ソフトウェア）、用途（遺伝子治療用途、臨床研究用途、診断用途、その他用途）、最終用途（病院・診断研究所最終用途、製薬・バイオ企業最終用途、研究・学術機関最終用途）

調査対象企業の例

  • Abbott Laboratories
  • Abcam plc
  • Active Motif, Inc.
  • Agilent Technologies Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Boehringer Ingelheim GmbH
  • Diagenode Diagnostics S.A.
  • Eli Lilly and Company
  • Epigenomics AG
  • EpiGentek Group Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Illumina, Inc.
  • Merck KGaA
  • New England Biolabs
  • Novartis International AG
  • Pacific Biosciences Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP30557

Global DNA Methylation Market to Reach US$4.1 Billion by 2030

The global market for DNA Methylation estimated at US$1.8 Billion in the year 2024, is expected to reach US$4.1 Billion by 2030, growing at a CAGR of 14.6% over the analysis period 2024-2030. Polymerase Chain Reaction Technology, one of the segments analyzed in the report, is expected to record a 17.4% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Microarray Technology segment is estimated at 11.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$476.1 Million While China is Forecast to Grow at 13.6% CAGR

The DNA Methylation market in the U.S. is estimated at US$476.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$631.1 Million by the year 2030 trailing a CAGR of 13.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.9% and 12.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.4% CAGR.

Global DNA Methylation Market - Key Trends & Drivers Summarized

Is DNA Methylation Unlocking New Frontiers in Epigenetic Diagnostics and Therapeutics?

DNA methylation, a key epigenetic mechanism, is emerging as a crucial biomarker for understanding and diagnosing a wide array of diseases, particularly cancer, neurological disorders, and autoimmune conditions. By adding a methyl group to the cytosine base in DNA, this process can regulate gene expression without altering the underlying genetic code. Its role in gene silencing, chromatin remodeling, and genome stability makes it a valuable target for both research and clinical applications. In oncology, aberrant DNA methylation patterns serve as early indicators of tumorigenesis, allowing for the development of highly sensitive diagnostic tools that detect cancers at their earliest stages, sometimes even before symptoms appear. Liquid biopsy platforms now leverage circulating tumor DNA (ctDNA) methylation signatures for non-invasive cancer screening, offering immense potential for population-wide early detection programs. Moreover, in neurodegenerative diseases like Alzheimer’s and Parkinson’s, specific methylation changes are being explored as biomarkers for early diagnosis and disease progression tracking. This expanding clinical utility has propelled demand for high-throughput methylation analysis technologies such as bisulfite sequencing, methylation arrays, and methylation-specific PCR. Pharmaceutical companies are also exploring DNA methylation as a therapeutic target, aiming to develop epigenetic drugs that can reverse abnormal methylation and restore normal gene function. As the clinical and research communities continue to unveil the functional implications of methylation patterns across various tissues and diseases, the DNA methylation market is witnessing significant growth, underpinned by a growing understanding of the epigenome’s role in health and disease.

How Are Innovations in Detection Technologies Transforming the DNA Methylation Landscape?

Rapid advancements in detection technologies are reshaping the way researchers and clinicians study DNA methylation, enhancing both resolution and scalability. Traditional methods like methylation-specific PCR and bisulfite conversion techniques, while still widely used, are being complemented by next-generation platforms such as whole-genome bisulfite sequencing (WGBS), reduced representation bisulfite sequencing (RRBS), and third-generation sequencing technologies like Oxford Nanopore and PacBio, which enable direct methylation detection without the need for chemical treatment. These newer tools provide higher accuracy, broader genomic coverage, and the ability to detect subtle changes in methylation patterns that may be missed by older technologies. High-throughput methylation arrays, such as Illumina’s Infinium platforms, are now capable of profiling hundreds of thousands of CpG sites across the genome in a single experiment, making them indispensable for epigenome-wide association studies (EWAS). Additionally, single-cell methylation sequencing is gaining traction, offering insights into cell-specific epigenetic landscapes and enabling discoveries in developmental biology and disease heterogeneity. The integration of artificial intelligence and machine learning is further amplifying these capabilities by allowing automated pattern recognition and predictive modeling of methylation-based disease markers. Moreover, portable and point-of-care methylation detection systems are being developed, particularly for cancer diagnostics in low-resource settings, highlighting a push toward more democratized epigenetic testing. These technological innovations are not only enhancing research efficiency but are also accelerating the clinical translation of DNA methylation findings, positioning it as a central pillar in precision medicine strategies.

Is the Growing Emphasis on Personalized Medicine Expanding Demand for Methylation-Based Tools?

The ongoing shift toward personalized and precision medicine is significantly boosting demand for DNA methylation analysis as a tool for individualized diagnostics, prognostics, and therapeutic decisions. In cancer care, for instance, methylation profiling helps stratify patients by tumor subtype, aggressiveness, and likely treatment response, enabling oncologists to tailor therapies more effectively. Companies are developing companion diagnostics based on methylation patterns to guide the use of specific drugs, particularly in cancers of the lung, breast, and colon. In prenatal testing, methylation-based assays are being used to distinguish fetal DNA from maternal DNA in non-invasive prenatal screening (NIPS), increasing the accuracy of detecting genetic anomalies without invasive procedures. Methylation biomarkers are also being explored in psychiatry to understand the epigenetic effects of environmental stressors and their impact on mental health, paving the way for predictive and preventive interventions. Moreover, with lifestyle, nutrition, and environmental exposures known to influence the methylome, consumer-oriented epigenetic testing services are gaining popularity, offering insights into aging, wellness, and disease predisposition based on an individual’s methylation profile. The combination of methylation data with other omics layers-such as transcriptomics and proteomics-is creating comprehensive patient profiles that can drive more informed clinical decision-making. Biopharmaceutical companies are increasingly integrating methylation analysis into drug discovery pipelines, using it to identify novel targets, validate disease models, and monitor epigenetic drug effects in real-time. As patient expectations evolve and healthcare shifts toward more proactive, data-driven models, the demand for DNA methylation-based solutions is poised to grow across both clinical and consumer health sectors.

What Are the Key Growth Catalysts Propelling the DNA Methylation Market Forward?

The growth in the DNA methylation market is driven by several factors rooted in technological maturity, disease-focused applications, evolving clinical practices, and user demand for precision diagnostics. Foremost among these is the expanding role of methylation biomarkers in cancer diagnostics, particularly for early detection and monitoring, where methylation signatures offer superior sensitivity compared to traditional genetic mutations. This is leading to the development and commercialization of new liquid biopsy tests, including FDA-approved assays, that are changing how cancers are diagnosed and managed. Additionally, the rise of multi-omics research is fueling demand for integrated platforms that include methylation analysis as a core component of biological insight generation. The increasing prevalence of complex, chronic diseases like neurodegeneration, autoimmune disorders, and metabolic syndromes is prompting more comprehensive investigations into epigenetic mechanisms, with methylation emerging as a key focus. Moreover, the growing trend of decentralized and home-based testing is creating a need for simplified, user-friendly methylation assays that maintain laboratory-level accuracy. On the institutional side, academic research initiatives and public health programs are incorporating large-scale methylation profiling to understand population-level disease risk, supported by increased funding from government and philanthropic organizations. The availability of cloud-based bioinformatics tools and scalable analytics is enabling broader adoption of methylation technologies even in resource-constrained settings. Meanwhile, pharmaceutical companies are using methylation profiling to identify patient subsets for targeted therapies and to monitor drug efficacy, especially in the development of epigenetic drugs. Finally, increasing regulatory approvals and the emergence of standardization frameworks for methylation-based diagnostics are providing the necessary validation and trust to expand market adoption. Collectively, these diverse yet interconnected drivers are propelling the DNA methylation market toward a more prominent and impactful role in the future of medicine and molecular research.

SCOPE OF STUDY:

The report analyzes the DNA Methylation market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology, Other Technologies); Product (Consumables, Kits & Reagents, Enzymes, Instruments & Software); Application (Gene Therapy Application, Clinical Research Application, Diagnostics Application, Other Applications); End-Use (Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use, Research & Academia End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 37 Featured) -

  • Abbott Laboratories
  • Abcam plc
  • Active Motif, Inc.
  • Agilent Technologies Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Boehringer Ingelheim GmbH
  • Diagenode Diagnostics S.A.
  • Eli Lilly and Company
  • Epigenomics AG
  • EpiGentek Group Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Illumina, Inc.
  • Merck KGaA
  • New England Biolabs
  • Novartis International AG
  • Pacific Biosciences Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • DNA Methylation - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Focus on Epigenetics in Disease Pathogenesis Throws the Spotlight on DNA Methylation Analysis
    • Growing Use of Methylation Biomarkers in Cancer Diagnostics Propels Demand for Precision Detection Tools
    • Expansion of Liquid Biopsy Technologies Strengthens Business Case for Non-Invasive Methylation Testing
    • Advancements in Sequencing and Bisulfite Conversion Methods Accelerate Adoption of High-Resolution Profiling
    • Integration of AI and Bioinformatics in Epigenetic Data Interpretation Drives Clinical Utility and Research Efficiency
    • Increasing Role of Methylation in Personalized Medicine Expands Addressable Market for Targeted Assays
    • Emergence of Single-Cell Methylation Technologies Spurs Innovation in Developmental and Tumor Biology
    • Growing Applications in Neurological and Autoimmune Diseases Generate Opportunities Beyond Oncology
    • Adoption of DNA Methylation in Aging and Wellness Research Spurs Growth in Consumer Epigenetics
    • Rising Demand for Companion Diagnostics Drives Development of Therapy-Linked Methylation Assays
    • Proliferation of Multi-Omics Research Platforms Enhances Integration of Methylation Data with Genomics and Proteomics
    • Expansion of Epigenetic Drug Development Pipelines Creates Synergy Between Therapeutics and Diagnostics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World DNA Methylation Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for DNA Methylation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for DNA Methylation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Polymerase Chain Reaction Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Polymerase Chain Reaction Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Microarray Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Microarray Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Sequencing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Clinical Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Clinical Research Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Diagnostics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Gene Therapy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Gene Therapy Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital & Diagnostics Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Hospital & Diagnostics Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Research & Academia End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Research & Academia End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Kits & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Enzymes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Enzymes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Instruments & Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World 6-Year Perspective for Instruments & Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • DNA Methylation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 34: USA Recent Past, Current & Future Analysis for DNA Methylation by Technology - Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for DNA Methylation by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies for the Years 2025 & 2030
    • TABLE 36: USA Recent Past, Current & Future Analysis for DNA Methylation by Application - Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: USA 6-Year Perspective for DNA Methylation by Application - Percentage Breakdown of Value Sales for Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application for the Years 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for DNA Methylation by End-Use - Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA 6-Year Perspective for DNA Methylation by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use for the Years 2025 & 2030
    • TABLE 40: USA Recent Past, Current & Future Analysis for DNA Methylation by Product - Consumables, Kits & Reagents, Enzymes and Instruments & Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: USA 6-Year Perspective for DNA Methylation by Product - Percentage Breakdown of Value Sales for Consumables, Kits & Reagents, Enzymes and Instruments & Software for the Years 2025 & 2030
  • CANADA
    • TABLE 42: Canada Recent Past, Current & Future Analysis for DNA Methylation by Technology - Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for DNA Methylation by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies for the Years 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for DNA Methylation by Application - Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada 6-Year Perspective for DNA Methylation by Application - Percentage Breakdown of Value Sales for Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application for the Years 2025 & 2030
    • TABLE 46: Canada Recent Past, Current & Future Analysis for DNA Methylation by End-Use - Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Canada 6-Year Perspective for DNA Methylation by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use for the Years 2025 & 2030
    • TABLE 48: Canada Recent Past, Current & Future Analysis for DNA Methylation by Product - Consumables, Kits & Reagents, Enzymes and Instruments & Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Canada 6-Year Perspective for DNA Methylation by Product - Percentage Breakdown of Value Sales for Consumables, Kits & Reagents, Enzymes and Instruments & Software for the Years 2025 & 2030
  • JAPAN
    • DNA Methylation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for DNA Methylation by Technology - Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan 6-Year Perspective for DNA Methylation by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies for the Years 2025 & 2030
    • TABLE 52: Japan Recent Past, Current & Future Analysis for DNA Methylation by Application - Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Japan 6-Year Perspective for DNA Methylation by Application - Percentage Breakdown of Value Sales for Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application for the Years 2025 & 2030
    • TABLE 54: Japan Recent Past, Current & Future Analysis for DNA Methylation by End-Use - Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Japan 6-Year Perspective for DNA Methylation by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use for the Years 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for DNA Methylation by Product - Consumables, Kits & Reagents, Enzymes and Instruments & Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan 6-Year Perspective for DNA Methylation by Product - Percentage Breakdown of Value Sales for Consumables, Kits & Reagents, Enzymes and Instruments & Software for the Years 2025 & 2030
  • CHINA
    • DNA Methylation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 58: China Recent Past, Current & Future Analysis for DNA Methylation by Technology - Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: China 6-Year Perspective for DNA Methylation by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies for the Years 2025 & 2030
    • TABLE 60: China Recent Past, Current & Future Analysis for DNA Methylation by Application - Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: China 6-Year Perspective for DNA Methylation by Application - Percentage Breakdown of Value Sales for Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application for the Years 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for DNA Methylation by End-Use - Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China 6-Year Perspective for DNA Methylation by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use for the Years 2025 & 2030
    • TABLE 64: China Recent Past, Current & Future Analysis for DNA Methylation by Product - Consumables, Kits & Reagents, Enzymes and Instruments & Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: China 6-Year Perspective for DNA Methylation by Product - Percentage Breakdown of Value Sales for Consumables, Kits & Reagents, Enzymes and Instruments & Software for the Years 2025 & 2030
  • EUROPE
    • DNA Methylation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 66: Europe Recent Past, Current & Future Analysis for DNA Methylation by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for DNA Methylation by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for DNA Methylation by Technology - Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe 6-Year Perspective for DNA Methylation by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies for the Years 2025 & 2030
    • TABLE 70: Europe Recent Past, Current & Future Analysis for DNA Methylation by Application - Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Europe 6-Year Perspective for DNA Methylation by Application - Percentage Breakdown of Value Sales for Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application for the Years 2025 & 2030
    • TABLE 72: Europe Recent Past, Current & Future Analysis for DNA Methylation by End-Use - Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Europe 6-Year Perspective for DNA Methylation by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use for the Years 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for DNA Methylation by Product - Consumables, Kits & Reagents, Enzymes and Instruments & Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe 6-Year Perspective for DNA Methylation by Product - Percentage Breakdown of Value Sales for Consumables, Kits & Reagents, Enzymes and Instruments & Software for the Years 2025 & 2030
  • FRANCE
    • DNA Methylation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 76: France Recent Past, Current & Future Analysis for DNA Methylation by Technology - Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: France 6-Year Perspective for DNA Methylation by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies for the Years 2025 & 2030
    • TABLE 78: France Recent Past, Current & Future Analysis for DNA Methylation by Application - Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: France 6-Year Perspective for DNA Methylation by Application - Percentage Breakdown of Value Sales for Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application for the Years 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for DNA Methylation by End-Use - Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France 6-Year Perspective for DNA Methylation by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use for the Years 2025 & 2030
    • TABLE 82: France Recent Past, Current & Future Analysis for DNA Methylation by Product - Consumables, Kits & Reagents, Enzymes and Instruments & Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: France 6-Year Perspective for DNA Methylation by Product - Percentage Breakdown of Value Sales for Consumables, Kits & Reagents, Enzymes and Instruments & Software for the Years 2025 & 2030
  • GERMANY
    • DNA Methylation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 84: Germany Recent Past, Current & Future Analysis for DNA Methylation by Technology - Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Germany 6-Year Perspective for DNA Methylation by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies for the Years 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for DNA Methylation by Application - Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany 6-Year Perspective for DNA Methylation by Application - Percentage Breakdown of Value Sales for Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application for the Years 2025 & 2030
    • TABLE 88: Germany Recent Past, Current & Future Analysis for DNA Methylation by End-Use - Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Germany 6-Year Perspective for DNA Methylation by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use for the Years 2025 & 2030
    • TABLE 90: Germany Recent Past, Current & Future Analysis for DNA Methylation by Product - Consumables, Kits & Reagents, Enzymes and Instruments & Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Germany 6-Year Perspective for DNA Methylation by Product - Percentage Breakdown of Value Sales for Consumables, Kits & Reagents, Enzymes and Instruments & Software for the Years 2025 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for DNA Methylation by Technology - Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy 6-Year Perspective for DNA Methylation by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies for the Years 2025 & 2030
    • TABLE 94: Italy Recent Past, Current & Future Analysis for DNA Methylation by Application - Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Italy 6-Year Perspective for DNA Methylation by Application - Percentage Breakdown of Value Sales for Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application for the Years 2025 & 2030
    • TABLE 96: Italy Recent Past, Current & Future Analysis for DNA Methylation by End-Use - Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Italy 6-Year Perspective for DNA Methylation by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use for the Years 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for DNA Methylation by Product - Consumables, Kits & Reagents, Enzymes and Instruments & Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy 6-Year Perspective for DNA Methylation by Product - Percentage Breakdown of Value Sales for Consumables, Kits & Reagents, Enzymes and Instruments & Software for the Years 2025 & 2030
  • UNITED KINGDOM
    • DNA Methylation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 100: UK Recent Past, Current & Future Analysis for DNA Methylation by Technology - Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: UK 6-Year Perspective for DNA Methylation by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies for the Years 2025 & 2030
    • TABLE 102: UK Recent Past, Current & Future Analysis for DNA Methylation by Application - Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: UK 6-Year Perspective for DNA Methylation by Application - Percentage Breakdown of Value Sales for Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application for the Years 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for DNA Methylation by End-Use - Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK 6-Year Perspective for DNA Methylation by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use for the Years 2025 & 2030
    • TABLE 106: UK Recent Past, Current & Future Analysis for DNA Methylation by Product - Consumables, Kits & Reagents, Enzymes and Instruments & Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 107: UK 6-Year Perspective for DNA Methylation by Product - Percentage Breakdown of Value Sales for Consumables, Kits & Reagents, Enzymes and Instruments & Software for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 108: Rest of Europe Recent Past, Current & Future Analysis for DNA Methylation by Technology - Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Rest of Europe 6-Year Perspective for DNA Methylation by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies for the Years 2025 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for DNA Methylation by Application - Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe 6-Year Perspective for DNA Methylation by Application - Percentage Breakdown of Value Sales for Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application for the Years 2025 & 2030
    • TABLE 112: Rest of Europe Recent Past, Current & Future Analysis for DNA Methylation by End-Use - Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Rest of Europe 6-Year Perspective for DNA Methylation by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use for the Years 2025 & 2030
    • TABLE 114: Rest of Europe Recent Past, Current & Future Analysis for DNA Methylation by Product - Consumables, Kits & Reagents, Enzymes and Instruments & Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Rest of Europe 6-Year Perspective for DNA Methylation by Product - Percentage Breakdown of Value Sales for Consumables, Kits & Reagents, Enzymes and Instruments & Software for the Years 2025 & 2030
  • ASIA-PACIFIC
    • DNA Methylation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for DNA Methylation by Technology - Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific 6-Year Perspective for DNA Methylation by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies for the Years 2025 & 2030
    • TABLE 118: Asia-Pacific Recent Past, Current & Future Analysis for DNA Methylation by Application - Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Asia-Pacific 6-Year Perspective for DNA Methylation by Application - Percentage Breakdown of Value Sales for Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application for the Years 2025 & 2030
    • TABLE 120: Asia-Pacific Recent Past, Current & Future Analysis for DNA Methylation by End-Use - Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Asia-Pacific 6-Year Perspective for DNA Methylation by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use for the Years 2025 & 2030
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for DNA Methylation by Product - Consumables, Kits & Reagents, Enzymes and Instruments & Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific 6-Year Perspective for DNA Methylation by Product - Percentage Breakdown of Value Sales for Consumables, Kits & Reagents, Enzymes and Instruments & Software for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 124: Rest of World Recent Past, Current & Future Analysis for DNA Methylation by Technology - Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Rest of World 6-Year Perspective for DNA Methylation by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Microarray Technology, Sequencing Technology and Other Technologies for the Years 2025 & 2030
    • TABLE 126: Rest of World Recent Past, Current & Future Analysis for DNA Methylation by Application - Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Rest of World 6-Year Perspective for DNA Methylation by Application - Percentage Breakdown of Value Sales for Clinical Research Application, Diagnostics Application, Other Applications and Gene Therapy Application for the Years 2025 & 2030
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for DNA Methylation by End-Use - Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of World 6-Year Perspective for DNA Methylation by End-Use - Percentage Breakdown of Value Sales for Hospital & Diagnostics Laboratories End-Use, Pharma & Biotech Companies End-Use and Research & Academia End-Use for the Years 2025 & 2030
    • TABLE 130: Rest of World Recent Past, Current & Future Analysis for DNA Methylation by Product - Consumables, Kits & Reagents, Enzymes and Instruments & Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Rest of World 6-Year Perspective for DNA Methylation by Product - Percentage Breakdown of Value Sales for Consumables, Kits & Reagents, Enzymes and Instruments & Software for the Years 2025 & 2030

IV. COMPETITION